Analyst Ratings January 29, 2026

Evercore Lifts Meta Platforms Price Target to $900, Cites AI-Driven Revenue Inflection

Analysts raise targets after stronger-than-expected quarterly results and robust guidance, spotlighting ad recovery and heavy capex for AI ambitions

By Leila Farooq META
Evercore Lifts Meta Platforms Price Target to $900, Cites AI-Driven Revenue Inflection
META

Evercore ISI raised its price objective on Meta Platforms Inc. (NASDAQ: META) to $900 from $875 and kept an Outperform rating, reflecting a bullish view tied to AI-related revenue prospects and recent quarterly beats. The adjustment sits alongside a market consensus that rates the stock as a strong buy and follows Meta's better-than-expected fourth-quarter results and accelerated first-quarter revenue outlook.

Key Points

  • Evercore ISI raised its price target on Meta to $900 from $875 and maintained an Outperform rating, based on a 25x multiple of its 2027 EPS estimate of $36.
  • InvestingPro data shows a strong buy consensus rating of 1.33 for Meta, with some analysts projecting targets as high as $1,117; the new Evercore target implies about 25% upside.
  • Meta reported Q4 2025 EPS of $8.88 versus $8.19 expected and revenue of $59.9 billion versus $58.35 billion expected; the company projected aggressive FY2026 capex growth of approximately $55 billion and total expenditure growth of approximately 40%.

Evercore ISI has increased its price target for Meta Platforms Inc. to $900 from $875 while maintaining an Outperform recommendation on the shares. The change is calibrated against Evercore’s model that applies a multiple of 25 to its 2027 earnings per share estimate of $36, yielding the new target.

According to InvestingPro data cited alongside the research move, Meta carries a strong buy consensus rating of 1.33, with some of the most optimistic analysts placing targets as high as $1,117. Evercore’s lift to $900 implies roughly a 25% upside from the current market price, based on the firm’s stated assumptions.

Market valuation metrics highlighted in the accompanying analysis show Meta trading at a price-to-earnings ratio of 29.65 and commanding an approximate enterprise value of $1.69 trillion. InvestingPro’s Fair Value model indicates that, by its methodology, the stock is fairly valued at present.

Evercore’s revision followed Meta’s fourth-quarter performance, which topped expectations, and management’s first-quarter revenue outlook that outpaced estimates. The company signaled a 7-point acceleration to about 30% year-over-year revenue growth on an ex-FX basis for the first quarter, a pace that drew analyst attention.

Profitability remains strong by several measures: InvestingPro data shows Meta retaining gross profit margins of 82.01%.

Separately, Meta provided ambitious fiscal year 2026 capital spending guidance, forecasting capex growth of approximately $55 billion and total expenditure expansion of approximately 40%. Evercore observers interpreted the guidance as consistent with management’s push to lead in artificial intelligence, noting that the firm’s model implies a roughly $50 billion revenue step-up in 2026 that supports an "AI-driven revenue inflection point." That characterization aligns with management’s stated objective to be an AI leader.

Meta’s reported fourth-quarter 2025 financials reinforced the bullish analyst response. The company posted earnings per share of $8.88, beating the consensus forecast of $8.19, and reported revenue of $59.9 billion versus an expected $58.35 billion.

In the wake of those results, multiple research firms adjusted their price targets. Canaccord Genuity raised its target to $930 while keeping a Buy rating and cited growth in advertising revenue. DA Davidson lifted its target to $850 after noting that Meta beat both revenue and earnings projections. Truist Securities increased its target to $900 and retained a Buy rating, pointing to Meta’s strong first-quarter guidance that projects growth of about 30%. Oppenheimer, by contrast, reiterated a Perform rating and described Meta’s fundamentals as at peak levels, attributing that strength to AI-enhanced engagement and new product introductions.

Collectively, the analyst moves and company disclosures signal that investors and strategists are weighing a combination of robust top-line momentum, sizable near-term investment, and AI-related revenue potential when reassessing Meta’s outlook.


Context and implications

The series of target changes and the posture from Evercore emphasize three themes evident in the data: solid recent operating performance, a step-up in projected investment for 2026, and an expectation that AI initiatives will materially influence revenue. These elements are central to how research firms are re-evaluating Meta’s valuation and growth trajectory.

Risks

  • High projected capital expenditures - Meta’s guidance for approximately $55 billion in capex growth and about 40% total expenditure growth for FY2026 increases execution and financing risk for the company and could pressure margins if investments do not yield expected revenue gains.
  • Valuation sensitivity - With the stock trading at a P/E of 29.65 and an implied market value near $1.69 trillion, future returns are sensitive to earnings execution; any slowdown versus the analyst assumptions could affect market sentiment.
  • Dependence on AI-driven revenue assumptions - Evercore’s thesis includes an implied roughly $50 billion revenue step-up in 2026 that reflects an "AI-driven revenue inflection point"; if AI initiatives do not materialize into the anticipated revenue, projected upside could be at risk.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026